drugset / Trial / NCT00826150
Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of DTA-H19 administered intraperitoneally (IP) in subjects with advanced stage ovarian cancer, or primary peritoneal carcinoma
Timeline
- Start
- 2009-06
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | inodiftagene vixteplasmid | Other / unclassified | 60 mg | Other |
| Subject | inodiftagene vixteplasmid | Other / unclassified | 120 mg | Other |
| Subject | inodiftagene vixteplasmid | Other / unclassified | 240 mg | Other |